Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: Results from a randomised, dose-finding study (DARWIN 2)

Annals of the Rheumatic Diseases

Volumn 76, Issue 6, 2017, Pages 1009-1019

  Kavanaugh, A ^a   Kremer, J ^b   Ponce, L ^c   Cseuz, R ^d   Reshetko, O V ^e   Stanislavchuk, M ^f   Greenwald, M ^g   Van Der Aa, A ^h   Vanhoutte, F ^h   Tasset, C ^h   Harrison, P ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c Consulta Privada Dra Lucia Ponce ^*  (Chile)

^d Revita Reumatologiai Rendelo   (Hungary)

^e Clinical Hospital   (Russian Federation)

^f Vinnitsa Regional Clinical Hospital   (Ukraine)

^g Desert Medical Advances   (United States)

^h GALAPAGOS NV   (Belgium)

Author keywords

DAS28; Rheumatoid Arthritis; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIMALARIAL AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; CORTICOSTEROID; CREATININE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FILGOTINIB; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PLACEBO; TRIACYLGLYCEROL LIPASE; ANTIRHEUMATIC AGENT; JANUS KINASE 1; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; CELLULITIS; CHOLESTEROL BLOOD LEVEL; CHRONIC PYELONEPHRITIS; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DAS28; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; HEALTH ASSESSMENT QUESTIONNAIRE; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; HUMERUS FRACTURE; INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; OSTEOARTHRITIS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SIMPLIFIED DISEASE ACTIVITY INDEX; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUBERCULOSIS; URINARY TRACT INFECTION; VITILIGO; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DISABILITY; METABOLISM; ORAL DRUG ADMINISTRATION; QUESTIONNAIRE; RETREATMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBINS; HUMANS; INFECTION; JANUS KINASE 1; MALE; METHOTREXATE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; RETREATMENT; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; TRIAZOLES;

EID: 85007190313     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-210105     Document Type: Article

References (13)

1. Jeurissen ME, Boerbooms AM, van de Putte LB, et al. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. Ann Intern Med 1991;114:999-1004.
2. Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: Abridged Cochrane systematic review and network meta-Analysis. BMJ 2016;353:i1777.
3. Möller RB, von Kempis J, Haile SR, et al. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Semin Arthritis Rheum 2015;45:28-34.
4. Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 2016;12:25-36.
5. Pfizer Inc. Xeljanz® (tofacitinib) prescribing information. Last revised Nov 2012.
6. Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs 2014;23:1067-77.
7. Namour F, Desrivot J, Van der Aa A, et al. Clinical confirmation that the selective JAK1 inhibitor filgotinib (GLPG0634) has a low liability for drug-drug interactions. Drug Metab Lett 2016;10:38-48.
8. Galien R, Brys R, Van der Aa A, et al. Absence of effects of filgotinib on erythrocytes, CD8+ and NK cells in rheumatoid arthritis patients brings further evidence for the JAK1 selectivity of filgotinib. [abstract] Arthritis Rheumatol 2015;67 (Suppl 10):2781.
9. Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013;191:3568-77.
10. Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet 2015;54:859-74.
11. Vanhoutte F, Mazur M. Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-Term treatment of rheumatoid arthritis; results of a phase IIA trial. Ann Rheum Dis 2012;71(Suppl 3):145.
12. Ongenaert M, Dupont S, Vayssière B, et al. Treatment of rheumatoid arthritis patients with the JAK1-selective inhibitor GLPG0634 reverses an arthritis-specific blood gene signature to healthy state. [abstract] Arthritis Rheumatol 2015;66(Suppl 10):1494.
13. Tasset C, Harrison P, van der Aa A, et al. The JAK1-selective inhibitor GLPG0634 is safe and rapidly reduces disease activity in patients with moderate to severe rheumatoid arthritis; results of a 4-week dose ranging study. [abstract] Arthritis Rheumatol 2013;65(Suppl 10):2381.